Kristie-ann Dickson
Ultimo, NSW 2007, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Drug repurposing in gynaecological cancers: Proven drugs for new challenges.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: September 26, 2025
Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer.
Journal: Therapeutic advances in medical oncology
Published: May 25, 2025
Revealing genetic drivers of ovarian cancer and chemoresistance: insights from whole-genome CRISPR-knockout library screens.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: May 08, 2025
Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer.
Journal: Molecular therapy. Oncology
Published: August 28, 2024
Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant Subtypes.
Journal: Cancers
Published: August 09, 2024
SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling.
Journal: Cancer letters
Published: June 14, 2024
AURKB and PI3K/AKT/mTOR pathways converge to regulate TERT expression.
Journal: iScience
Published: March 18, 2024
CRISPR single base-editing: in silico predictions to variant clonal cell lines.
Journal: Human molecular genetics
Published: May 03, 2023
Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.
Journal: Cancers
Published: July 08, 2022
Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine.
Journal: Frontiers in bioengineering and biotechnology
Published: December 16, 2021
Last Updated: 09/26/2026